All AbMole products are for research use only, cannot be used for human consumption.
Nintedanib (BIBF1120) is a novel, potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
Nintedanib (BIBF1120) inhibits mitogen-activated protein kinase and Akt signaling pathways in three cell types contributing to angiogenesis, endothelial cells, pericytes, and smooth muscle cells, resulting in inhibition of cell proliferation (EC50, 10–80 nmol/L) and apoptosis.
 |
Source | Oncotarget (2015). Figure 5. BIBF1120 |
| Method | Western blots | |
| Cell Lines | SKOV3 cells | |
| Concentrations | 5 μM | |
| Incubation Time | 24 h | |
| Results | We utilized a custom-made siRNA library for the six mesenchymal signature genes to test the differences in the nintedanib effects on E-cadherin induction |
 |
Source | Oncotarget (2015). Figure 4. BIBF1120 |
| Method | Western blots | |
| Cell Lines | SKOV3 cells | |
| Concentrations | 5 μM | |
| Incubation Time | 24 h | |
| Results | Furthermore, 5 μM nintedanib concomitantly up-regulated both E-cadherin protein and CDH1 transcript levels |
| Cell Experiment | |
|---|---|
| Cell lines | HUVEC, HSMEC, BRP, HUASMC, FaDu, Calu-6 and Hela cells line |
| Preparation method | Cell proliferation and apoptosis assays.[3H]Thymidine incorporation assay for proliferation analysis and apoptosis assay was performed as previously described. |
| Concentrations | 0~5µM |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | Human FaDu (squamous cell carcinoma of the head and neck) xenografts growing in nude mice |
| Formulation | not mentioned |
| Dosages | 10, 50, 100 mg/kg |
| Administration | orally |
| Molecular Weight | 539.62 |
| Formula | C31H33N5O4 |
| CAS Number | 656247-17-5 |
| Solubility (25°C) | DMSO 6 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related VEGFR/PDGFR Products |
|---|
| Conbercept
Conbercept (KH902) is a monoclonal antibody targeting VEGFRA fused to the IGHG1 Fc fragment. Conbercept is produced by the fusion of the second C-LIKE of FLT1 and the third and fourth C-LIKE of KDR with IGHG1 Fc. |
| SU5208
SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2). |
| VEGFR-IN-1
VEGFR-IN-1 is a potent angiogenesis inhibitor with IC50s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively. |
| (Z)-Orantinib
(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 µM, respectively. |
| (Rac)-SAR131675
(Rac)-SAR131675 is the racemate of SAR131675. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
